Patients treated in the intensive care unit can present with post-intensive care syndrome, a spectrum of psychiatric, cognitive, and/or physical disability (e.g., muscle weakness, cognitive dysfunction, insomnia, depression, anxiety, post-traumatic stress disorder, delirium, encephalopathy) that affects survivors of critical illness, and persists after the patient has been discharged from the intensive care unit. Weakness affects 33% of patients who receive mechanical ventilation, 50% of patients with sepsis, and <50% of patients who remain in the intensive care unit for more than 1 week. Cognitive dysfunction affects 30% to 80% of patients. The risk can be minimized with medication management, physical rehabilitation, family support, and follow-up clinics. Physical, mental, or cognitive symptoms were reported frequently in patients who survived 1 year following intensive care unit.
A hypercoagulable state is one of the hallmarks of disease, particularly in critically ill patients, often manifesting as venous and arterial thromboembolism. The coagulopathy in COVID-19 has a prothrombotic character, with increases in D-dimer, fibrin, fibrin degradation products, and fibrinogen. Antiphospholipid antibodies have been detected in patients with severe and critical disease; however, there does not currently appear to be any association between this finding and disease outcomes (e.g., thrombosis, mortality).
Epidemiology: the pooled incidence of venous thromboembolism, deep vein thrombosis, and pulmonary embolism among hospitalized patients was 14.7%, 11.2%, and 7.8%, respectively. The prevalence was significantly higher in patients admitted to the intensive care unit, despite thromboprophylaxis. The prevalence of arterial thromboembolism appears to be lower at 3.9%; however, evidence is limited. Thromboembolic events are rare in children. The risk factors with the most evidence for being predictive of venous thromboembolism are older age and elevated D-dimer levels. Male sex, obesity, mechanical ventilation, intensive care unit admission, severe parenchymal abnormalities, and elevated white blood cells have also been identified as risk factors. The cumulative incidence of acute pulmonary embolism and deep vein thrombosis among recovered patients after hospital discharge was 1.2% and 2.3%, respectively, much lower compared with the in-hospital incidence. Nonhospitalized patients may also be at increased risk of thromboembolic events.
Etiology: the pathogenesis is not completely understood. It has been hypothesized that local thrombi are formed due to a local inflammatory process, rather than the classical emboli coming from elsewhere in the body. Patients may be predisposed to thromboembolism due to the direct effects of infection, or the indirect effects of infection (e.g., severe inflammatory response, critical illness, traditional risk factors). Thrombotic events may be due to cytokine storm, hypoxic injury, endothelial dysfunction, hypercoagulability, and/or increased platelet activity.
Diagnosis: monitor patients for signs or symptoms suggestive of venous or arterial thromboembolism, and proceed according to hospital protocols for diagnosis. Admission D-dimer level has been associated with venous thromboembolism diagnosis during hospitalization; however, there are no optimal thresholds to guide prophylaxis measures. Evaluate hospitalized patients who experience rapid deterioration of pulmonary, cardiac, or neurologic function, or sudden localized loss of peripheral perfusion, for thromboembolic disease.
Management: treat patients with a thromboembolic event (or who are highly suspected to have thromboembolic disease if imaging is not possible) with therapeutic anticoagulation. Low molecular weight heparin or unfractionated heparin is preferred over oral anticoagulants. Treat patients who require extracorporeal membrane oxygenation or continuous renal replacement therapy, or who have thrombosis of catheters or extracorporeal filters, with antithrombotic therapy as per the standard institutional protocols for those without COVID-19.
Monitoring: hematologic and coagulation parameters are commonly measured in hospitalized patients; however, there is currently insufficient evidence to recommend either for or against using such data to guide management decisions. Patients with very high D-dimer levels have the greatest risk of thrombosis and may benefit from active monitoring.
Prognosis: patients with thromboembolic events have 1.93 times the odds of dying compared with patients without venous thromboembolism.
Also see Disseminated intravascular coagulation below.
Cardiovascular complications include arrhythmias, myocardial injury, acute coronary syndrome, and heart failure. While acute infection was associated with a six-fold increase in cardiovascular diagnoses overall, the risk began to decline 5 weeks after infection and returned to baseline levels or below from 12 weeks to 1 year.
Epidemiology: cardiovascular complications have been reported in 14.1% of patients during hospitalization. The overall pooled incidence of acute myocardial infarction, heart failure, arrhythmias, cardiac arrest, and acute coronary syndrome were 21%, 14%, 16%, 3.45%, and 1.3%, respectively. Higher rates of myocardial injury have been reported in the US (9% to 52%) compared with China (7% to 28%). A Cochrane review found that the most common cardiovascular complications were arrhythmias, heart failure, and arterial and venous occlusive events. More rarely, cases of fulminant myocarditis, pericarditis, cardiac tamponade, cor pulmonale, and takotsubo syndrome have been reported. Risk factors include older age, hypertension, underlying cardiovascular disease, and chronic kidney disease.
Etiology: COVID-19 is associated with a high inflammatory burden. Inflammation of the myocardium can result in myocarditis, heart failure, arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death.
Diagnosis: perform an ECG and order high-sensitivity troponin I (hs-cTnI) or T (hs-cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with symptoms or signs that suggest acute myocardial injury in order to make a diagnosis. The following test results may help inform the diagnosis: evolving ECG changes suggesting myocardial ischemia; NT-proBNP level >400 nanograms/L; high levels of hs-cTnI or hs-cTnT, particularly levels increasing over time. Elevated troponin levels may reflect cardiac inflammatory response to severe disease rather than acute coronary syndrome. Seek specialist cardiology advice on further tests and imaging.
Management: seek specialist cardiology advice on treatment and follow local treatment protocols. There are limited data to recommend any specific drug treatments for these patients. Involve a multidisciplinary team including intensive care specialists, cardiologists, and infectious disease specialists.
Monitoring: monitor blood pressure, heart rate, and fluid balance, and perform continuous ECG monitoring in all patients with suspected or confirmed acute myocardial injury. Monitor in a setting where cardiac or respiratory deterioration can be rapidly identified. Laboratory biomarkers may help identify those at greater risk of developing cardiovascular complications. Elevated cardiac biomarkers and emerging arrhythmias are associated with the development of severe disease and need for intensive care admission.
Prognosis: myocardial injury is associated with poor outcomes and survival. Elevated troponin predicts a poor outcome and higher risk of mortality. An overall case fatality rate of 9.6% has been reported. Infection may have longer-term implications for overall cardiovascular health. Cardiovascular problems have been reported up to 1 year after infection, including in those who were not hospitalized for the acute infection.
Acute kidney injury is common, particularly in critically ill patients. It can develop at any time before, during, or after hospital admission.
Epidemiology: the pooled incidence of acute kidney injury has been estimated to be 19.45%; however, incidence varies across studies. Patients have a significantly increased risk of in-hospital mortality (54.2%). Independent risk factors included male sex, older age, smoking history, obesity, hypertension, diabetes, pneumopathy, cardiovascular disease, cancer, chronic kidney disease, mechanical ventilation, and use of vasopressors.
Etiology: causes include hemodynamic changes, hypovolemia, viral infection leading directly to kidney tubular injury, thrombotic vascular processes, glomerular pathology, or rhabdomyolysis. May be associated with hematuria, proteinuria, and abnormal serum electrolyte levels (e.g., potassium, sodium).
Diagnosis: monitor patients for signs or symptoms suggestive of acute kidney injury, and proceed according to hospital protocols for diagnosis.
Management: follow local guidelines for managing acute kidney injury. Supportive measures and fluid management are required. Potassium binders may be used as options alongside standard care for the emergency management of acute life-threatening hyperkalemia. Continuous renal replacement therapy (CRRT) is recommended in critically ill patients with acute kidney injury who develop indications for renal replacement therapy; prolonged intermittent renal replacement therapy is recommended over hemodialysis if CRRT is not available or possible.
Monitoring: monitor patients with chronic kidney disease for at least 2 years after acute kidney injury.
Also known as post-acute COVID-19, post-acute COVID-19 syndrome, post-COVID conditions, chronic COVID, long-haul COVID, and post-acute sequelae of SARS-CoV-2 infection (PASC).
Definition: case definitions vary. The World Health Organization defines it as a condition that occurs in adults with a history of probable or confirmed SARS-CoV-2 infection, usually occurring 3 months from the onset of symptoms and lasting for at least 2 months, that cannot be explained by an alternative diagnosis. A clinical case definition for children and adolescents is also available. The UK National Institute for Health and Care Excellence defines post-COVID-19 syndrome as signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis. Ongoing symptomatic COVID-19 is defined as signs and symptoms from 4 weeks up to 12 weeks. The term long COVID may be used to describe either of these case definitions. The Centers for Disease Control and Prevention defines post-COVID conditions as an umbrella term for the wide range of health consequences that are present more than 4 weeks after infection with SARS-CoV-2. The syndrome is not thought to be linked to disease severity during the acute phase of illness. Protracted symptoms are common after many viral and bacterial infections, including influenza. However, while the clinical features were also observed after influenza infection, the incidence appears to be higher after COVID-19. The neurologic symptoms are similar to symptoms of other neurologic conditions such as chronic fatigue syndrome and functional neurologic disorder. Evidence from cross-sectional studies suggests that persistent physical symptoms after COVID-19, particularly fatigue, may be associated more with the belief in having been infected than with having laboratory-confirmed infection. Laboratory-confirmed infection was associated only with anosmia. Findings suggest that persistent physical symptoms after infection should not be automatically ascribed to COVID-19, but further research is required.
Epidemiology: frequency ranges from 4.7% to 80% across observational studies. Risk factors include female sex, age, previous hospitalization, and the presence of certain comorbidities (e.g., pulmonary disease, diabetes, obesity, organ transplantation, smoking). Approximately 63% of patients reported at least one symptom at 30 days after symptom onset/hospitalization, with 71% reporting at least one symptom after 60 days, and 46% at 90 days or more in a systematic review and meta-analysis. In another systematic review, 54% of patients reported at least one symptom at 1 month, 55% of patients reported at least one symptom at 2 to 5 months, and 54% of patients reported at least one symptom at 6 months or longer. However, some studies report much lower rates of continuing symptoms after 12 weeks (2.3% to 3%). A study that corrected for individual symptoms present before COVID-19 and the symptom dynamics in the population without SARS-CoV-2 infection found that 12.7% of patients are likely to experience long-term symptoms at 90 to 150 days after infection. Persistent symptoms have been reported up to 12 months after discharge, but most people had a good and functional recovery during 1-year follow-up. Persistent symptoms have also been reported at 2-year follow-up in a significant number of patients, with fatigue and muscle weakness being the most frequent. Prolonged illness can occur among young adults with no underlying comorbidities, and in patients who had mild disease. Approximately 12% to 15% of patients who had mild symptoms still had symptoms up to 8 months later. The number of symptoms at follow-up was associated with the symptom load during the acute phase of infection and the number of comorbidities in nonhospitalized patients. Asymptomatic infection is associated with a lower risk of developing long-term sequelae. Persistent symptoms have been reported in pregnant women and children. A meta-analysis found the prevalence was 25% in children and adolescents, with the most prevalent symptoms being mood symptoms, fatigue, and sleep disorders. However, evidence in children is limited, heterogeneous, and based on low-quality studies. Low-certainty evidence suggests that vaccination before SARS-CoV-2 infection may reduce the risk of long COVID. The impact of vaccination in people with existing long COVID is inconsistent. The risk of developing long COVID may be lower among people infected with the Omicron variant compared with those infected with previous variants. Long COVID caused by different variants appears to have no clinical differences, except in certain symptoms (e.g., myalgia, sleep difficulty).
Diagnosis: use a holistic, person-centered approach that includes a comprehensive clinical history (including history of suspected or confirmed acute COVID-19, nature and severity of previous and current symptoms, timing and duration of symptoms since the start of acute illness, and a history of other health conditions), and appropriate examination that involves assessing physical, cognitive, psychological, and psychiatric symptoms, as well as functional abilities. Refer patients with signs or symptoms that could be caused by an acute or life‑threatening complication (e.g., severe hypoxemia, signs of severe lung disease, cardiac chest pain, multisystem inflammatory syndrome in children) urgently to the relevant acute services. After ruling out acute or life-threatening complications and alternative diagnoses, consider referring people to an appropriate service, such as an integrated multidisciplinary assessment service, any time from 4 weeks after the start of acute COVID‑19.
Signs and symptoms: symptoms vary widely, may relapse and remit or fluctuate, can change unpredictably, and can occur in those with mild disease only. Common long-term symptoms include, but are not limited to, persistent cough, low-grade fever, breathlessness, weakness, malaise, impairment of concentration, fatigue, pain, chest pain/tightness, palpitations, myalgia, arthralgia, headaches, vision changes, hearing loss, earache, tinnitus, sore throat, loss of taste/smell, nasal congestion, impaired mobility, peripheral neuropathy, dizziness, tremors, memory loss, mood changes, skin rashes, hair loss, sexual dysfunction, gastrointestinal symptoms, neurocognitive difficulties, sleep disturbances, delirium (older people), and mental health conditions (e.g., anxiety, depression, post-traumatic stress disorder). Children and older people may not have the most commonly reported symptoms. The following symptoms and signs are less commonly reported in children and younger people: dyspnea; persistent cough; pain on breathing; palpitations; heart rate variations; chest pain. The most common symptoms at 1-year follow-up were fatigue, sweating, chest tightness, anxiety, and myalgia. Some of the symptoms may overlap with post-intensive care syndrome (see above). Patients may be at increased risk for new-onset diabetes, but whether preexisting diabetes is a risk factor for long COVID remains unclear. The inability to return to normal activities, emotional and mental health outcomes, and financial loss are common.
Investigations: tailor investigations to the clinical presentation, and to rule out any acute or life-threatening complications and alternative diagnoses. Investigations may include blood tests (e.g., complete blood count, kidney and liver function tests, C-reactive protein, ferritin, B-type natriuretic peptide, glycosylated hemoglobin [HbA1c], thyroid function), oxygen saturation, blood pressure and heart rate measurements, exercise tolerance test, chest imaging, electrocardiogram, and psychiatric assessment. Approximately 50% of patients had residual abnormalities on chest CT and pulmonary function tests at 3 months. After 1 year, 32.6% of patients still had residual CT abnormalities (usually fibrotic changes). Abnormalities were more frequent in patients who had severe/critical disease compared with mild/moderate disease. Around 9% of patients had deteriorating chest x-ray appearances at follow-up, which may indicate lung fibrosis. Persistently elevated D-dimer and C-reactive protein have also been reported. The prevalence of pulmonary fibrosis has been reported as 44.9% in one meta-analysis.
Management: give advice and information on self-management including ways to self-manage symptoms (e.g., set realistic goals, antipyretic for fever, breathing techniques for chronic cough, home pulse oximetry for monitoring breathlessness, pulmonary rehabilitation, staged return to exercise); who to contact if there is concern about symptoms or if there is need for support; sources of support (e.g., support groups, online forums); and how to get support from other services (e.g., social care, housing, financial support). There is a lack of evidence for pharmacologic interventions to treat the condition. A personalized, multidisciplinary rehabilitation plan that covers physical, psychological, and psychiatric aspects of rehabilitation is an important part of management. Many patients recover spontaneously with holistic support, rest, symptomatic treatment, and a gradual increase in activity. Referral to a specialist may be required in patients where there is clinical concern along with respiratory, cardiac, or neurologic symptoms that are new, persistent, or progressive. The World Health Organization makes several recommendations for the rehabilitation of adults with post-COVID-19 condition. Consensus guidelines on the specific management of children, cardiovascular complications, fatigue, breathing discomfort, autonomic dysfunction, and cognitive symptoms are also available from the American Academy of Physical Medicine and Rehabilitation.
Follow-up: recovery time differs but symptoms resolve by 12 weeks in most people. Agree with the patient how often follow-up and monitoring are needed (either in person or remotely), and which healthcare professionals should be involved. Take into account the patient’s level of need and the services involved. Tailor monitoring to the patient’s symptoms, and consider supported self-monitoring at home (e.g., heart rate, blood pressure, pulse oximetry). Be alert to symptoms that could require referral or investigation.
Myocarditis or pericarditis may occur following vaccination with mRNA vaccines. It has been postulated that mRNA vaccines may increase inflammation on the endothelium and T-cell infiltration of cardiac muscle, but further research is required as various mechanisms have been hypothesized. Cases have also been reported with adenovirus vector vaccines and protein subunit vaccines, albeit more rarely.
Epidemiology: the incidence of myocarditis may be as high as 140 cases per million doses depending on age and sex. Male adolescents and young adults are at the highest risk; the incidence is highest in males ages 12 to 29 years. Myocarditis is more likely with the Moderna vaccine compared with the Pfizer/BioNTech vaccine, and is more likely after the second dose (data for incidence rates after a third dose are limited, although the manufacturer states that the risk profile is similar after the second and third doses). On average, symptom onset was 2 to 4 days after the vaccine dose, although intervals of up to 20 days (or longer) have been reported. Incidence after the second dose may be lower when administered ≥31 days after the first dose compared with ≤30 days among younger age groups. For pericarditis, data were limited but more variation than myocarditis has been reported in patient age, sex, onset timing, and rate of admission to hospital. Reported rates in immunocompromised people were similar to the general population.
Diagnosis: consider the diagnosis in children, adolescents, or adults with new-onset and unexplained significant chest pain, tachycardia or tachypnea, dyspnea, palpitations, dizziness or syncope, or general clinical concern, within 10 days of vaccination (note: patients may also present >10 days after vaccination). The most common presenting symptom was chest pain (34.5%).
Investigations: order a 12-lead ECG, inflammatory blood markers, complete blood count, and troponin. If ECG or troponin are abnormal, discuss the management plan with the cardiology team. Further investigations (e.g., cardiac imaging and rhythm monitoring) and follow-up should be led by the cardiology team. The most common findings were ST-related changes on an electrocardiogram (58.7%) and hypokinesia on cardiac magnetic resonance imaging or echocardiography (50.7%). Laboratory findings included elevated troponin I levels (81.7%) and elevated C-reactive protein (71.5%).
Management: strenuous physical activity should be avoided until symptoms improve. Patients should be referred to a cardiologist as management depends on the clinical presentation.
Prognosis: up to 93% of adolescents and young adults required hospital admission, with intensive care unit admission required in up to 25% of patients. Median interval from onset to approval for all physical activity was 98 days. Approximately 81% of patients who completed a follow-up healthcare provider survey were considered recovered at follow-up at least 90 days since onset. However, approximately half of patients continued to self-report symptoms (e.g., chest pain), and 25% were prescribed daily cardiac medications.
Consult your local public health authority for guidance on administering further doses of a COVID-19 vaccine. Some countries have implemented age-related prescribing restrictions for mRNA vaccines due to the risk of myocarditis/pericarditis. Modifying mRNA vaccine programs to incorporate age-based product considerations and longer interdose intervals may reduce the risk of myocarditis/pericarditis.
Liver injury may be associated with preexisting liver disease, viral infection, drug toxicity, systemic inflammation, hypoxia, or hemodynamic issues; however, the underlying mechanism is unclear. The overall prevalence has been reported as 25%, although there is no uniform definition of liver injury in these patients and prevalence depends on the definition used in studies. The overall prevalence may be as low as 9% when strict criteria for diagnosis are used. The prevalence of elevated alanine aminotransferase and aspartate aminotransferase was 19% and 22%, respectively. The prevalence of hypertransaminasemia was higher in patients with severe disease compared with patients with nonsevere disease. Abnormal liver function tests are associated with significantly higher mortality, intensive care unit admission, and mechanical ventilation requirements. Another meta-analysis concluded that findings from the available evidence to date from observational studies and case reports indicate that transaminases and total bilirubin levels appear not to significantly change in patients with COVID-19.
Risk factors associated with severe liver injury include older age, preexisting liver disease, and severe disease. Medications used in the treatment of COVID-19 (e.g., remdesivir, tocilizumab) may have a detrimental effect on liver injury. Guidelines on the management of liver derangement in patients with COVID-19 have been published.
Neurologic complications include acute cerebrovascular disease, impairment of consciousness, ataxia, seizures, status epilepticus, encephalopathy, encephalitis and meningoencephalitis, acute disseminated encephalomyelitis, corticospinal tract signs, demyelinating lesions, peripheral neuropathies, parkinsonism, cerebral venous sinus thrombosis, myopathy, Guillain-Barre syndrome, dementia, and abnormal findings on brain magnetic resonance imaging. Burning mouth syndrome and burning eye syndrome have been reported.
Patients commonly have central or peripheral neurologic complications, possibly due to viral invasion of the central nervous system, inflammatory response, or immune dysregulation. Neurologic complications occur across the lifespan in the context of infection, with and without known comorbidities, and with all disease severities (including asymptomatic patients). Patients may present with these manifestations, or they may develop them during the course of the disease (usually 1 to 2 weeks after the onset of respiratory disease). Patients with preexisting neurologic disorders may develop an exacerbation of their neurologic symptoms. Long-term sequelae may be possible.
Epidemiology: reported in 22% to 35% of patients. Central nervous system manifestations were more common than peripheral nervous system manifestations. Neurologic involvement is common in children and adolescents (22% in patients ages <21 years).
Acute cerebrovascular disease: (including ischemic stroke, hemorrhagic stroke, cerebral venous thrombosis, and transient ischemic attack) has been reported in 0.5% to 5.9% of patients. The most common type was ischemic stroke (0.4% to 4.9%). However, the overall absolute incidence of stroke in inpatients has been reported as 0.175%, lower than that reported in previous observational studies. Patients with severe disease are at an increased risk of ischemic stroke compared with patients with nonsevere disease. Stroke is relatively frequent among hospitalized patients relative to other viral respiratory infections, and has a high risk of in-hospital mortality. Risk factors include older age and male sex. Median time from onset of COVID-19 symptoms to stroke was 8 days. Stroke presents later in severe disease, and earlier in mild to moderate disease. Patients may present with ischemic stroke during the convalescent phase of infection, including younger people <50 years of age with asymptomatic or pauci-symptomatic COVID-19. Ischemic stroke appears to be more severe and result in worse outcomes (severe disability) in patients with COVID-19, with the median NIH Stroke Scale score being higher among those with COVID-19 compared with those without. Guidelines for the management of acute ischemic stroke in patients with COVID-19 infection have been published.
Guillain-Barre syndrome: both post-infectious and pre-infectious patterns have been reported. The pooled prevalence among hospitalized and nonhospitalized patients was 0.15%. The mean age of patients was 55 years with a male predominance. Most patients had respiratory and/or severe symptoms of COVID-19, although it has also been reported in asymptomatic patients. A higher prevalence of the classic sensorimotor form and acute inflammatory demyelinating polyneuropathy have been reported, although rare variants have also been noted. Patients had an increased odds for demyelinating subtypes. Clinical outcomes were comparable to those for contemporary or historical controls not infected with SARS-CoV-2.
Encephalitis: has been reported in <1% of patients overall, but increases up to 6.7% in critically ill patients. Encephalitis is associated with poorer outcomes including admission to the intensive care unit, need for mechanical ventilation, and increased mortality rate (13.4%) compared with the general population of COVID-19 patients. Rare cases of autoimmune encephalitis have been reported.
In-hospital cardiac arrest is common in critically ill patients, and is associated with poor survival, particularly among older patients. Among 5019 critically ill patients with COVID-19, 14% had an in-hospital cardiac arrest. Risk factors included older age, male sex, presence of comorbidities, and admission to a hospital with a smaller number of intensive care unit beds. Approximately 57% of patients received cardiopulmonary resuscitation. The most common rhythms at the time of resuscitation were pulseless electrical activity (49.8%) and asystole (23.8%). Of those who received resuscitation, 12% survived to hospital discharge with most of these patients being younger than 45 years of age.
Pregnancy outcome is usually good, although there are little data on exposure during early pregnancy. The risk for complications was higher in pregnant women who were symptomatic. The risk of maternal and neonatal complications appeared to be substantially less during the Omicron-dominant period compared with the pre-Omicron period. Lower-income countries have reported higher rates of maternal intensive care unit admission and mortality, and stillbirths, compared with higher-income countries.
Maternal outcomes: the odds of admission to the intensive care unit, invasive ventilation, and need for extracorporeal membrane oxygenation were higher in pregnant and recently pregnant women compared with nonpregnant reproductive-aged women. Pregnant women may also be at an increased risk of maternal death. Risk factors for serious complications include preexisting comorbidities (e.g., chronic hypertension, diabetes), high maternal age, non-White ethnicity, presence of pregnancy-specific conditions (e.g., gestational diabetes, preeclampsia), and high body mass index. A statistically significant higher risk of gestational diabetes, gestational hypertension, poor fetal growth, and preeclampsia was reported in pregnant women during the pandemic period compared with the prepandemic period.
Preterm birth: preterm birth was more common in pregnant women with COVID-19 compared with pregnant women without the disease. However, the overall rates of spontaneous preterm births in pregnant women with COVID-19 was broadly similar to those observed in the prepandemic period, so these preterm births could have been medically indicated.
Stillbirth and neonatal death: the overall rates of stillbirths and neonatal deaths do not seem to be higher than the background rates. In England, there is no evidence of an increase in stillbirths regionally or nationally during the pandemic when compared with the same months in the previous year and despite variable community infection rates in different regions. However, in the US, women with COVID-19 were at an increased risk for stillbirth compared with women without COVID-19 during the period of March 2020 to September 2021, with the magnitude of association being higher during the Delta variant predominance. An individual participant data meta-analysis found no link between infection during pregnancy with an increased risk of stillbirth at or beyond 28 weeks’ gestation or with intrauterine growth restriction.
Neonatal infection: limited low-quality evidence suggests that the risk of infection in neonates is extremely low. Most infections are acquired in the postpartum period, although congenitally acquired infection has been reported. Unlike children who generally have asymptomatic infection, two-thirds of neonatal cases are symptomatic and a significant proportion require intensive care, although the overall prognosis appears to be excellent.
Neonatal outcomes: there is limited and conflicting evidence of an increased risk of short- or long-term neonatal morbidity (e.g., respiratory disease), and further research is required. There is some evidence that maternal infection and perinatal transmission has the potential to affect the auditory system of the newborn, especially during the second and third trimester of pregnancy. However, data are limited and inconsistent and further research is required.
Sepsis (diagnosed according to Sepsis-3 or according to the presence of infection-related organ dysfunction necessitating organ support/replacement) has been reported in 78% of intensive care unit patients and 33% of hospitalized patients.
Guidelines for the management of shock in critically ill patients with COVID-19 recommend a conservative fluid strategy (crystalloids preferred over colloids, buffered/balanced crystalloids preferred over unbalanced crystalloids) and a vasoactive agent. Norepinephrine (noradrenaline) is the preferred first-line agent in adults (epinephrine [adrenaline] or norepinephrine may be used in children). Vasopressin or epinephrine (adrenaline) can be added to norepinephrine in adults if target mean arterial pressure cannot be achieved with norepinephrine alone. Ultimately, patients who require fluid resuscitation or hemodynamic management of shock should be treated and managed identically to patients with septic shock. Consult your local guidelines for more information.
Disseminated intravascular coagulation (DIC) is a manifestation of coagulation failure, and an intermediate link in the development of multi-organ failure. Patients may be at high risk of bleeding/hemorrhage or venous thromboembolism. The pooled incidence of DIC is 3%, and it is associated with poor prognosis. The incidence was higher in patients with severe disease and those admitted to the intensive care unit, and in nonsurvivors compared with survivors. COVID-19-associated coagulopathy appears to be distinct from DIC, although DIC has been reported in severely affected patients. The coagulation changes in COVID-19 patients mimic, but are not identical to, DIC, and the vast majority of patients do not meet the criteria for usual forms of DIC.
Coagulopathy manifests as elevated fibrinogen, elevated D-dimer, and minimal change in prothrombin time, partial thromboplastin time, and platelet count in the early stages of infection. Increasing interleukin-6 levels correlate with increasing fibrinogen levels. Coagulopathy appears to be related to severity of illness and the resultant thromboinflammation. Monitor D-dimer level closely.
Anticoagulant therapy with a low molecular weight heparin or unfractionated heparin has been associated with a better prognosis in patients with severe COVID-19 who have a sepsis-induced coagulopathy (SIC) score of ≥4 or a markedly elevated D-dimer level. In patients with heparin-induced thrombocytopenia (or a history of it), argatroban or bivalirudin are recommended.
Standard guidance for the management of bleeding manifestations associated with DIC or septic coagulopathy should be followed if bleeding occurs; however, bleeding manifestations without other associated factors is rare.
The leading cause of death is respiratory failure from acute respiratory distress syndrome. Children can quickly progress to respiratory failure. Patients with COVID-19 may have a higher risk of developing ventilator-associated pneumonia compared with patients without COVID-19. Overall, ventilator-associated pneumonia was reported in 48.2% of mechanically ventilated patients and the mortality rate was 51.4%.
Air leak (pneumothorax, pneumomediastinum, and subcutaneous emphysema) is associated with higher mortality and longer hospital stay, especially in older people, and can occur even without positive pressure ventilation. It is mainly due to disease progression resulting in inflammatory insult to lung parenchyma and ventilatory stress-induced alveolar damage. The incidence varies widely across studies and increases with disease severity. The mean age of patients was 58 years and 75% were male. Hypertension was the most common comorbidity, followed by diabetes. Isolated pneumothorax was the most common type of air leak (48.5%), with 17% of patients developing a spontaneous pneumothorax. Mortality was 40%. Further research is required.
Some patients with severe disease have laboratory evidence of an unregulated inflammatory response similar to cytokine release syndrome, characterized by plasma leakage, increased vascular permeability, diffuse intravascular coagulation, and immunodeficiency. These patients have a poor prognosis. High serum levels of proinflammatory cytokines, particularly interleukin-6, have been identified in these patients. Features of secondary hemophagocytic lymphohistiocytosis may be present. Treatment options include interleukin-6 inhibitors (e.g., tocilizumab), Janus kinase inhibitors (e.g., baricitinib), and anakinra.
Also see Pediatric inflammatory multisystem syndrome, a cytokine release syndrome-like illness in children, below.
Also known as pediatric inflammatory multisystem syndrome (PIMS), pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS), as well as other variations. Multisystem inflammatory syndrome in adults (MIS-A) has also been reported, albeit more rarely.
Definition: a rare but serious delayed complication that may develop in children and adolescents approximately 3 to 4 weeks (or longer) after the onset of acute infection, likely due to a postinfectious inflammatory process. The syndrome resembles, but is distinct from, Kawasaki disease, and also shares common features with toxic shock syndrome. It has a strong temporal association with SARS-CoV-2 infection. The case definition generally includes the presence of fever, elevated inflammatory markers, multi-organ dysfunction, a history of a positive SARS-CoV-2 test (or close contact with a confirmed case), and no plausible alternative diagnosis. However, case definitions vary. Can occur rarely after COVID-19 vaccination.
Epidemiology: the risk of MIS-C within 2 months of confirmed infection was 0.05% in one Danish cohort study. A systematic review found that the median age of patients was 9.3 years of age, and 57% of patients were male. At least one comorbidity was reported in 31% of cases, most commonly obesity, asthma, and chronic lung disease. Risk factors for developing MIS-C include male sex, age 5 to 11 years, foreign-born parents, asthma, obesity, and life-limiting conditions. Factors associated with more severe outcomes included age >5 years; non-Hispanic Black ethnicity; symptoms of dyspnea or abdominal pain; elevated C-reactive protein, troponin, ferritin, D-dimer, brain natriuretic peptide, or interleukin-6; and reduced lymphocyte or platelet counts. Cases have been reported rarely in neonates (temporally associated with prenatal exposure), and there may be a higher risk of mortality in neonates compared with older children. There appears to be a lower risk of MIS-C with the Omicron variant.
Diagnosis: patients often have predominant cardiac dysfunction and gastrointestinal symptoms. The most common manifestations were fever (99%), gastrointestinal symptoms (87%), shock (66%), rash (59%), conjunctivitis (57%), cardiovascular manifestations (55%), oral mucosal changes (42%), respiratory symptoms (41%), neurologic symptoms (36%), and coronary artery aneurysms (22%). The pooled prevalence of significant left ventricular dysfunction was 38%, coronary aneurysm or dilatation was 20%, and ECG abnormalities/cardiac arrhythmias was 28%. Neonates commonly present with cardiorespiratory compromise. Approximately 20% of children develop acute kidney injury. Three types of clinical manifestations have been recognized: persistent fever and gastrointestinal symptoms (the most common type); shock with heart dysfunction; and symptoms coincident with the diagnostic criteria for Kawasaki disease. Patients with MIS-C presented more frequently with respiratory and gastrointestinal symptoms and shock compared with patients with Kawasaki disease; however, they had a lower incidence of conjunctivitis. Disease may be less severe after infection with the Omicron variant compared with Alpha and Delta variants.
Investigations: inflammatory and cardiac markers were elevated in the majority of patients, and 38% had abnormal findings on chest x-ray. Raised serum troponin level was reported in 33% of patients, and raised pro B-type natriuretic peptide (proBNP)/BNP level was reported in 44% of patients.
Management: management is mainly supportive and involves a multidisciplinary team. Approximately 79% of patients required intensive care admission, 63% required inotropic support, 57% required anticoagulation, and 33% required mechanical ventilation. The optimal choice and combination of immunomodulating therapies have not been definitively established. The World Health Organization recommends corticosteroids in addition to supportive care (rather than either intravenous immune globulin plus supportive care, or supportive care alone) in hospitalized children ages 0 to 18 years who meet the standard case definition. It also recommends corticosteroids in addition to supportive care in those who meet both a standard case definition for MIS-C and diagnostic criteria for Kawasaki disease. In the US, the National Institutes of Health guidelines panel recommends initial therapy with a combination of immunomodulatory therapy (i.e., intravenous immune globulin plus a low-to-moderate dose of corticosteroid) and antithrombotic therapy (i.e., low-dose aspirin plus anticoagulation in certain patients). Children who do not improve within 24 hours should be started on either anakinra, high-dose corticosteroids, or infliximab. Guidance has also been published by the American College of Rheumatology. Consult your local guidelines for further information.
Prognosis: the majority of patients had good outcomes with no significant medium- or long-term sequelae at 1-year follow-up. Follow-up at 6 months found that while cardiac, gastrointestinal, renal, hematologic, and otolaryngology outcomes largely resolved at 6 months, muscular fatigue and emotional lability were common. The mortality rate was 1.9%.
Future COVID-19 vaccination: there are limited data on the safety of COVID-19 vaccines in people who have had MIS-C or MIS-A and who have not yet received a vaccine. A history of MIS-C or MIS-A may be a precaution for vaccination. Consult your local guidelines for more information.
VITT is also known as thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). Evidence on this syndrome is limited. Some countries have implemented age-related prescribing restrictions for adenovirus-vector vaccines due to the risk of VITT.
Definition: prothrombotic disorder of thrombosis with concurrent thrombocytopenia and development of antiplatelet factor 4 (anti-PF4) antibodies occurring after vaccination with an adenovirus vector-based COVID-19 vaccine (e.g., AstraZeneca, Janssen). Thrombosis occurs in uncommon sites (e.g., cerebral venous sinus thrombosis, splanchnic vein thrombosis, arterial thrombosis) and may be multifocal. The syndrome clinically resembles heparin-induced thrombocytopenia. The exact pathophysiology remains unknown, but there are several hypotheses. Can be rapidly progressive and fatal. Cases have also been reported with mRNA vaccines, albeit more rarely.
Epidemiology: observational data from the UK suggest the risk for a thrombotic event was highest in people ages <40 years, at 16.1 and 36.3 per million doses, respectively, for cerebral venous thrombosis or another thrombosis event, with the greatest elevated risk within 4 to 13 days after vaccination. In the US, the overall risk with the Janssen vaccine has currently been estimated to be 3.83 cases per million people who receive the vaccine, with the reporting rate highest among women ages 30 to 39 years (10.6 cases per million doses) and 40 to 49 years (9.02 cases per million doses), with a case fatality rate of 15%. Cases have been reported up to 48 days after vaccination.
Diagnosis: advise vaccine recipients who experience any severe symptoms from around 4 to 30 days after vaccination to seek urgent medical attention. Approximately half of patients present with cerebral venous sinus thrombosis. Headache is the most common presenting symptom, and may precede VITT by several days. Signs and symptoms include: new-onset headache that is getting worse and does not respond to simple analgesics; an unusual headache that seems worse when lying down or bending over, or may be accompanied by blurred vision, nausea and vomiting, speech difficulty, weakness, drowsiness, or seizures; new unexplained pinprick bruising or bleeding; and shortness of breath, chest pain, leg swelling, or persistent abdominal pain. Ask about vaccination history in people with suspected VITT. Refer people who are acutely unwell to the emergency department immediately. Patients may rarely present with ischemic stroke. Report all cases to local health authorities and through local vaccine adverse event reporting systems.
Investigations: order a complete blood count (with platelets), coagulation screen (including fibrinogen and D-dimer), blood film/peripheral smear, and platelet factor 4 enzyme-linked immunosorbent assay for any patient presenting with acute thrombosis or new-onset thrombocytopenia within 42 days of receiving a COVID-19 vaccination. Typical laboratory features include thrombocytopenia, raised D-dimer levels above the level expected for venous thromboembolism, and low or normal fibrinogen. Antibodies to platelet factor 4 have also been identified. Order same-day imaging studies based on location of signs and symptoms to confirm the site of thrombosis. Repeat imaging may be required in patients whose blood tests suggest probable VITT, but no thrombosis is seen on initial imaging or there is clinical or laboratory suspicion of progression.
Differential: other possible causes of thrombocytopenia with thrombosis include cancer, antiphospholipid syndrome, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and paroxysmal nocturnal hemoglobinuria. Consider alternative diagnoses in people whose blood tests indicate it is unlikely they have VITT. A small number of people with VITT do not have thrombocytopenia at presentation. Therefore, repeat a complete blood count after 2 to 3 days or if symptoms worsen, if a high clinical suspicion of VITT remains. Discuss the need for further investigations with a hematologist.
Management: promptly treat patients. Consult a hematologist when making decisions about starting or adding treatments. There is limited information about the optimal treatment of this condition; however, management is similar to heparin-induced thrombocytopenia. First-line treatment is urgent administration of intravenous immune globulin. A second dose may be considered if there is an inadequate response after 2 to 3 days. Some experts also recommend the use of corticosteroids, especially if intravenous immune globulin treatment is insufficient. Anticoagulate with a nonheparin-based therapy such as a direct oral anticoagulant, fondaparinux, danaparoid, or argatroban, depending on the clinical picture, as soon as the benefit outweighs the risk of bleeding. Review response to anticoagulation if the patient’s clinical condition changes, and adjust treatment if needed. Avoid platelet transfusions (other than emergency situations), heparin (including heparin flushing solution), low molecular weight heparin, and vitamin K antagonists (e.g., warfarin). Heparin may be used if nonheparin-based anticoagulants are not available. Consider plasma exchange, fibrinogen replacement, or rituximab in select patients. Some patients may require surgery to treat thrombosis.
Monitoring: after discharge, the patient should be under the care of a hematologist. Assess symptoms and measure D-dimer, fibrinogen, and platelet counts every 2 to 3 days for the first 2 weeks. Repeat enzyme-linked immunosorbent assay (ELISA) for platelet factor 4 antibodies weekly for the first 4 weeks. Repeat tests monthly for the first 6 months and, if no relapses occur, reduce the frequency of testing to every 3 months. When platelet 4 antibodies are no longer detected, review the need for ongoing treatment and monitoring.
Prognosis: mortality due to complications has been reported to be 39%. Fibrinogen levels, age, platelet count, and the presence of intracerebral hemorrhage or cerebral venous thrombosis are significantly associated with an increased risk of mortality. Consult local guidelines for advice on further vaccination after an episode of VITT.
Management is evolving and there are differences between the guidelines available. Consult the most current local guidelines for more detailed information on the diagnosis and management of this condition.
Thromboembolic events that are distinct from VITT may occur after vaccination with any COVID-19 vaccine, but most commonly occur after vaccination with adenovirus-vector vaccines. Venous thrombosis was more common than arterial thrombosis. Cerebral venous thrombosis was the most common manifestation in patients with venous thrombosis, followed by deep vein thrombosis. Myocardial infarction was common in patients with arterial thrombosis, followed by ischemic stroke. Adenovirus-vector vaccines may be associated with an increased incidence of pulmonary embolism and myocardial infarction in the second week after vaccination.
COVID-19-associated aspergillosis (CAPA) may occur in people who are critically ill. It is a recognized cause of a patient’s clinical condition not improving despite treatment.
Epidemiology: reported in 10.2% of patients admitted to the intensive care unit in one study. Risk factors include older age, chronic lung disease, intubation for more than 7 days, immunosuppression, and use of high-dose corticosteroids.
Diagnosis: consider diagnosis in patients who deteriorate despite optimal supportive care or who have other suspicious radiologic or clinical features. There are no specific signs or symptoms. Base your decisions on individual risk factors and the person's clinical condition, and involve a multidisciplinary team (including an infectious disease specialist). Frequently manifests as COVID-19 pneumonia without the common computed tomography scan abnormalities of pulmonary aspergillosis. Refer to your local protocols on the diagnosis of CAPA.
Investigations: use a range of tests to increase the likelihood of a confident diagnosis; include bronchoalveolar lavage, if possible. Test for antifungal resistance if an Aspergillus isolate is cultured. Do not order tests if there is a low clinical suspicion.
Management: antifungal therapy is recommended. Only use antifungal therapy if investigations support a diagnosis of CAPA, or CAPA is suspected but the results of investigations are not available yet. There is not enough evidence to recommend specific antifungals. Discuss treatment options with a multidisciplinary team (including an infectious disease specialist). Stop treatment if the results of investigations do not support the diagnosis. Refer to your local protocols on the management of CAPA.
Prognosis: a mortality rate of 54.9% was reported in one study.
Mucormycosis (also known as "black fungus") has been reported rarely, particularly in low- and middle-income countries, predominantly India. COVID-19-associated pulmonary mucormycosis is diagnosed either simultaneously with, or within 3 months of, virologically confirmed COVID-19. Case definitions for proven, probable, or possible pulmonary disease have been published. Coinfection with aspergillosis is possible.
Epidemiology: approximately 88% of cases were reported from low- or middle-income countries. Cases in India increased significantly during its second wave in early 2021. Cases have been reported in other countries, including the US. Risk factors include male sex, uncontrolled diabetes, and immunosuppression (e.g., due to corticosteroid therapy).
Diagnosis: have a low threshold of suspicion for diagnosis. It is important not to miss warning signs and symptoms (e.g., nasal congestion; blackish/bloody nasal discharge; sinus or facial pain; toothache or loosening of teeth; vision disturbances; hemoptysis; necrotic eschar on skin, palate, or nasal turbinates). Do not hesitate to order appropriate investigations. The median time to interval between diagnosis of COVID-19 and evidence of mucormycosis was 15 days. Rhino-orbital mucormycosis was most common (42%), followed by rhino-orbito-cerebral mucormycosis (24%), and pulmonary mucormycosis (10%). Cases of atypical-site mucormycosis have been reported, as well as cases in COVID-19 recovered patients. Do not hesitate to aggressively order investigations as appropriate for detecting fungal etiology. Flexible bronchoscopy and chest imaging are recommended to enable early diagnosis of pulmonary mucormycosis.
Management: management strategies include: controlling hyperglycemia, diabetes, or diabetic ketoacidosis; reducing corticosteroid dose with the aim to rapidly discontinue; discontinuing immunomodulating drugs; extensive surgical debridement to remove all necrotic material; antifungal therapy (e.g., amphotericin-B for initial therapy, followed by posaconazole or isavuconazole maintenance therapy or salvage therapy) for 4 to 6 weeks; and appropriate supportive care and monitoring. Patients should be under the care of a multidisciplinary team that includes an infectious disease specialist; an intensivist; a neurologist; a dentist; an ophthalmologist; an ear, nose, and throat specialist; and a surgeon.
Prevention: prevention involves controlling hyperglycemia; monitoring blood glucose level in COVID-19 patients after discharge (whether or not they are diabetic); and judicious use of corticosteroids, antibiotics, and antifungals.
Complications: rare cases of pulmonary artery pseudoaneurysm have been reported with COVID-19-associated pulmonary mucormycosis.
Prognosis: overall mortality rate has been reported to be 39%. The overall mortality in India (36.5%) was less than that for globally reported cases (61.9%), likely due to the predominance of rhino-orbital mucormycosis in India. Risk factors for increased mortality includes older age, specific comorbidities, aspergillus coinfection, and use of tocilizumab. A significant proportion of survivors had life-changing morbidities (e.g., vision loss). Patients with pulmonary and rhino-orbito-cerebral mucormycosis and those who receive medical treatment only are at increased risk for mortality.
The overall incidence of candidemia ranges from 0.7% to 23.5%, with most cases occurring in the intensive care unit in mechanically ventilated patients. Cases of candidemia due to Candida auris, an emerging multidrug-resistant pathogen, have been reported. Reasons for the increased incidence in this population are poorly understood; however, patients are exposed to multiple risk factors for candidemia including corticosteroid therapy, immunosuppressive therapy, antibiotics, and long stays in the intensive care unit. A high mortality rate has been reported.
Mild pancreatic injury (defined as elevated serum amylase or lipase levels) has been reported in 17% of patients in one case series. It is unknown whether this is a direct viral effect or due to the harmful immune response that occurs in some patients. Patients had an increased risk of severe pancreatitis and necrotizing pancreatitis, and a longer length of hospital stay. Patients with acute pancreatitis had a high pooled mortality (18.5%) and significantly worse clinical outcomes. The most common presenting symptom was abdominal pain. Prior history of pancreatitis does not appear to be a risk factor for pancreatic inflammation in patients with COVID-19. A causal relationship between SARS-CoV-2 infection and acute pancreatitis has not been established.
Immune thrombocytopenia has been reported rarely. The majority of cases were in patients >50 years of age, with only 7% of cases reported in children. The majority of cases were in patients with moderate to severe COVID-19; however, 7% of cases were in asymptomatic COVID-19 patients. Onset occurred in 20% of cases 3 weeks after the onset of COVID-19 symptoms, with most cases reported after clinical recovery. Severe life-threatening bleeding was uncommon. Treatment involved the use of corticosteroids, intravenous immune globulin, and thrombopoietin-receptor agonists.
Subacute thyroiditis is a thyroid disease of viral or post-viral origin. Emerging evidence suggests that infection with SARS-CoV-2 may trigger subacute thyroiditis, based on case reports and case studies. A review of 21 cases found a female predominance, with the mean number of days between the start of COVID-19 illness and the appearance of symptoms of subacute thyroiditis being 25 days. Infection had resolved in the majority of patients before the onset of subacute thyroiditis symptoms. Fever and neck pain were the most common presenting complaints. Symptoms resolved in all patients after treatment; however, 5 patients reported having hypothyroid illness on follow-up.
COVID-19 may also cause autoimmune thyroid disease or exacerbate underlying thyroid disease in remission. Cases of Grave disease, Hashimoto thyroiditis, and postpartum thyroiditis have been reported.
Critically ill patients may develop gastrointestinal complications; however, it is unclear whether this is a manifestation of critical illness in general, or whether it is specific to COVID-19. One study found that patients with COVID-19 were more likely to develop gastrointestinal complications compared with those without COVID-19, specifically transaminitis, severe ileus, and mesenteric ischemia. In patients with acute mesenteric ischemia, small-bowel ischemia was the most prevalent finding on abdominal computed tomography, followed by ischemic colitis. Nonocclusive mesenteric ischemia was the most common pattern of bowel involvement.
Macrovascular arterial/venous thrombosis has been identified in almost 50% of patients with bowel ischemia. Overall mortality in COVID-19 patients with gastrointestinal ischemia and radiologically evident mesenteric thrombotic occlusion was 38.7% and 40%, retrospectively. Patients with intestinal ischemia generally present with abdominal pain and vomiting. Management includes gastric decompression, fluids, hemodynamic support, and surgery.
Patients may have an increased risk of gastrointestinal bleeding compared with the general population; however, evidence is limited. The overall gastrointestinal bleeding rate has been reported to be 2%. Risk factors for gastrointestinal hemorrhage in COVID-19 patients include history of gastrointestinal bleeding and anticoagulant use.
Acute telogen effluvium, a type of diffuse hair loss, has been reported in patients recovering from infection. The median age of patients was 44 years, and most patients were female. The mean duration from COVID-19 symptom onset to the appearance of telogen effluvium was 74 days. Most patients recovered; however, a minority of patients had persistent hair fall. Stress may be a contributing factor. Cases of new-onset alopecia areata, as well as recurrences or exacerbations, have also been reported after infection.
There is emerging evidence that patients may rarely have signs, symptoms, and radiologic and laboratory features indicative of involvement of the lower urinary tract and male genital system. This may include scrotal discomfort, swelling, or pain (acute orchitis, epididymitis, or epididymo-orchitis); low-flow priapism; impaired spermatogenesis (including decreased sperm count, sperm concentration, sperm motility, and normal sperm morphology); bladder hemorrhage; acute urinary retention; and worsening of existing lower urinary tract symptoms (including exacerbation of benign prostatic hyperplasia). Semen parameters appear to return to normal as patients recover. Further research is required.
Parosmia (misperception of an odor) is a late-onset symptom that may develop approximately 3 months after infection. It may occur without any preceding apparent smell loss, or it may follow a short recovery period from initial anosmia. There are no effective, evidence-based treatments available; however, the patient should be offered useful tips on living with parosmia until recovery.
Use of this content is subject to our disclaimer